Vancouver, Canada, March 27, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the filing of a patent application in India covering innovative next-generation psychedelic-based compounds for the treatment of mental health disorders and addiction ...

Vancouver, Canada, March 19, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the successful continuation of treatment of participants in the third cohort of its ongoing FDA-approved Phase I/IIa clinical trial evaluating CMND-100, the Company’s ...

Core Viewpoint - Clearmind Medicine Inc. has announced the publication of six patents in Hong Kong, focusing on innovative combination therapies that integrate Palmitoylethanolamide (PEA) with various psychedelic compounds to address under-treated health issues [1][2][3] Group 1: Patent Publication and Innovations - The newly published patents protect formulations that combine PEA with MDMA, LSD, Ketamine, Ibogaine, Psilocybin, and DMT, aiming to enhance therapeutic potential and improve safety and tolerability for mental health and neurological conditions [2] - The company currently holds a total of nineteen patent families, which include 31 granted patents, and plans to seek additional patents as opportunities arise [5] Group 2: Company Strategy and Objectives - Clearmind is focused on developing non-hallucinogenic, neuroplastogen-derived therapeutics to tackle significant health problems, including alcohol use disorder [4] - The CEO emphasized the strategic combination of PEA with well-characterized psychedelics to build a robust pipeline of next-generation candidates aimed at addressing unmet needs in mental health [3]

Core Viewpoint - NeuroThera Labs Inc. has announced a collaboration with Clearmind Medicine Inc. to file a patent for an innovative combination therapy aimed at treating major depressive disorder (MDD) [1][3] Company Overview - NeuroThera Labs Inc. is a clinical-stage biotech company focused on developing novel therapeutics for central nervous system disorders through collaborations and innovative combinations [4] - Clearmind Medicine Inc. is a clinical-stage pharmaceutical biotech company dedicated to discovering and developing psychedelic-derived therapeutics for various health issues, including alcohol use disorder [5] Patent Filing and Therapy Details - Clearmind has filed a patent application in Hong Kong for a combination therapy that includes Clearmind's proprietary 5-methoxy-2-aminoindane (MEAI) and Palmitoylethanolamide (PEA) sourced from NeuroThera [2][3] - The MEAI-PEA combination is positioned as a non-hallucinogenic neuroplastogen option for treating depression, which affects over 332 million people globally [3] Market Potential and Advantages - The anticipated mechanism of action for the MEAI-PEA therapy suggests it could offer a safer, more accessible, and affordable alternative to existing antidepressants, including SSRIs [3][8] - There is a growing demand for novel treatments for major depressive disorder, highlighting the potential market opportunity for this combination therapy [8]

Core Insights - Clearmind Medicine Inc. has filed a patent application for a novel combination therapy aimed at treating major depressive disorder (MDD), which is projected to be a significant market exceeding $25 billion by 2030 [1][3] Company Overview - Clearmind is a clinical-stage biotech company focused on developing non-hallucinogenic neuroplastogen-derived therapeutics to address major health issues, including MDD and alcohol use disorder [4] - The company currently holds a portfolio of nineteen patent families, with 31 granted patents, and plans to pursue additional patents to enhance its intellectual property [5] Treatment Innovation - The new treatment combines Clearmind's proprietary 5-methoxy-2-aminoindane (MEAI) with Palmitoylethanolamide (PEA), developed in partnership with NeuroThera Labs Inc. [2] - This MEAI-PEA synergy is positioned as a safer and more accessible alternative to traditional antidepressants, potentially benefiting over 332 million people globally suffering from depression [3]

Exhibit 99.1 CLEARMIND MEDICINE INC. Condensed Interim Consolidated Financial Statements For The Three Months Ended January 31, 2026 (Expressed in United States Dollars) (Unaudited) CLEARMIND MEDICINE INC. Condensed Interim Consolidated Statements of Financial Position (Expressed in United States Dollars) (Unaudited) | | January 31, | | October 31, | | --- | --- | --- | --- | | | 2026 | | 2025 | | Assets | | | | | Current assets | | | | | Cash and cash equivalents | $ 9,257,766 | $ | 3,923,058 | | Other rec ...

Core Viewpoint - Clearmind Medicine Inc. is advancing its clinical trial for CMND-100, a non-hallucinogenic treatment for Alcohol Use Disorder (AUD), following positive results from previous cohorts [1][2][4]. Group 1: Clinical Trial Progress - The company is continuing participant enrollment for the third cohort of its FDA-approved Phase I/IIa clinical trial for CMND-100 [1]. - The second cohort's results showed continued safety and tolerability, leading to unanimous approval from the Data and Safety Monitoring Board (DSMB) to proceed with the next phase [2]. - The trial is a multinational, multicenter study aimed at evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of CMND-100 in patients with moderate to severe AUD [3]. Group 2: Company Insights - Clearmind Medicine focuses on developing novel, non-hallucinogenic therapeutics derived from neuroplastogens to address significant health issues, including AUD [5]. - The company holds an intellectual property portfolio consisting of nineteen patent families and 31 granted patents, with plans to seek additional patents as necessary [6].

Core Viewpoint - NeuroThera Labs Inc. has advanced its collaboration with Clearmind Medicine Inc. by publishing an international patent application for a novel combination therapy targeting weight loss and metabolic dysfunction-associated steatotic liver disease (MASLD) [1][2]. Company Overview - NeuroThera Labs Inc. is a clinical-stage biotech company focused on developing novel therapeutics for central nervous system disorders and other underserved health conditions through collaborations and innovative combinations [4]. - Clearmind Medicine Inc. is a clinical-stage neuroplastogens pharmaceutical biotech company dedicated to discovering and developing psychedelic-derived therapeutics for widespread health issues, including alcohol use disorder [5]. Market Potential - The combination therapy of 5-methoxy-2-aminoindane (MEAI) and Palmitoylethanolamide (PEA) is positioned to address obesity, which affects over 890 million adults globally, and MASLD, impacting approximately 30% of the global adult population [2]. - The global weight loss drugs market was valued at approximately $37 billion in 2025 and is projected to reach $226 billion by 2035, driven by increasing awareness of obesity as a chronic disease and the need for innovative alternatives to GLP-1 agonists [3]. Therapeutic Advantages - The MEAI-PEA combination may provide a safer, non-hallucinogenic neuroplastogen treatment option that is potentially more cost-effective than existing GLP-1 agonists for obesity and MASLD [2][3]. - The collaboration aims to meet the growing demand for effective, tolerable, and safe treatments in the obesity and liver health sectors [3].

Core Insights - Noble Mineral Exploration Inc. has successfully closed a non-brokered private placement, raising approximately $1,050,000 through the issuance of 7,000,000 flow-through common share units priced at $0.15 per unit [2][3] - The company plans to utilize the proceeds from the private placement to fund exploration expenditures for critical minerals on its properties [3] - Noble is also settling debt by paying $14,000 in cash and issuing 466,666 broker warrants, each exercisable for one common share at a price of $0.125 per share for two years [4] Private Placement - Noble raised gross proceeds of about $1,050,000 through the issuance of 7,000,000 flow-through common share units [2] - Each unit consists of one common share designated as a flow-through share and one-half non-flow-through common share purchase warrant, with full warrants exercisable for two years at an exercise price of $0.20 per share [2] - The securities issued are subject to a four-month hold period and customary closing conditions, including TSX Venture Exchange approval [3] Debt Settlement - Noble has received necessary approvals to settle debt, which includes a cash payment of $14,000 and the issuance of 466,666 broker warrants [4] - Each warrant from the debt settlement is exercisable for one common share at a price of $0.125 per share for two years [4] - All warrants issued in this transaction are also subject to a four-month hold period [4] Company Overview - Noble Mineral Exploration Inc. is a Canadian junior exploration company with holdings in various nickel and gold exploration properties [5][6] - The company holds mineral and exploration rights in approximately 70,000 hectares in Northern Ontario and 24,000 hectares in Quebec [6][7] - Notable projects include Project 81, which hosts drill-ready targets for gold, nickel-cobalt, and base metals, as well as several other properties focused on critical minerals [6][7]

Core Insights - Clearmind Medicine Inc. has announced an international patent application for a novel combination therapy using MEAI and PEA to treat obesity and metabolic dysfunction-associated steatotic liver disease (MASLD) [1][2] - The global market for weight loss drugs is projected to grow from approximately $37 billion in 2025 to $226 billion by 2035, driven by increasing awareness of obesity as a chronic disease [3] Company Overview - Clearmind is a clinical-stage biotech company focused on developing non-hallucinogenic neuroplastogen-derived therapeutics for under-treated health issues, including obesity and liver health [4] - The company currently holds nineteen patent families, including 31 granted patents, and aims to expand its intellectual property portfolio [5] Market Potential - The MEAI-PEA combination therapy targets two significant health challenges: obesity, which affects over 890 million adults globally, and MASLD, impacting about 30% of the adult population [2][7] - This therapeutic option may provide a safer and more cost-effective alternative to GLP-1 agonists for treating obesity and MASLD [2][7]